NSCLC (Non-small Cell Lung Cancer) research hub

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.